Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D8XHT1
|
|||
| Drug Name |
RGX-111
|
|||
| Drug Type |
Gene therapy
|
|||
| Indication | Mucopolysaccharidosis [ICD-11: 5C56.3; ICD-9: 277.5] | Phase 1 | [1] | |
| Company |
REGENXBIO
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Alpha-L-iduronidase (IDUA) | Target Info | Replacement | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03580083) RGX-111 Gene Therapy in Patients With MPS I. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of REGENXBIO. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.